NI201000071A - Una vacuna multicomponente o monocompon - Google Patents
Una vacuna multicomponente o monocomponInfo
- Publication number
- NI201000071A NI201000071A NI201000071A NI201000071A NI201000071A NI 201000071 A NI201000071 A NI 201000071A NI 201000071 A NI201000071 A NI 201000071A NI 201000071 A NI201000071 A NI 201000071A NI 201000071 A NI201000071 A NI 201000071A
- Authority
- NI
- Nicaragua
- Prior art keywords
- vaccine
- cruzi
- immunogenic
- immunogenic portion
- multicomponent
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 8
- 241000223109 Trypanosoma cruzi Species 0.000 abstract 8
- 230000002163 immunogen Effects 0.000 abstract 6
- 206010001935 American trypanosomiasis Diseases 0.000 abstract 5
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 208000024699 Chagas disease Diseases 0.000 abstract 3
- 102000040430 polynucleotide Human genes 0.000 abstract 3
- 108091033319 polynucleotide Proteins 0.000 abstract 3
- 239000002157 polynucleotide Substances 0.000 abstract 3
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 244000045947 parasite Species 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 230000005875 antibody response Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 108010004486 trans-sialidase Proteins 0.000 abstract 1
- 201000002311 trypanosomiasis Diseases 0.000 abstract 1
- 230000007923 virulence factor Effects 0.000 abstract 1
- 239000000304 virulence factor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/005—Trypanosoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
El objeto principal de la presente invención es una vacuna contra la enfermedad de Chagas, capaz de estimular la respuesta inmune contra el factor de virulencia trans-sialidasa del parásito Trvpanosoma cruzi, caracterizada dicha vacuna porque comprende una vacuna multicomponente para la enfermedad del Chagas (tripanosomiasis americana) caracterizada porque comprende: (a) una porción inmunógenica conformada por uno o mas polipéptidos recombinantes o sintéticos, o fracciones de ellos, y (b) uno o más polinucleótidos que comprenden a las regiones que codifican a uno o más polipéptidos inmunogénicos, ambas porciones para los derivados de los Trypanosoma cruzi ( es decir de un T. Cruzi y/o una región conservada común a varios de ellos) donde la administración de dicha vacuna protege de la infección del parásito, lo elimina o atenúa las consecuencias clínicas de dicha infección. Otro objeto de la presente invención es una vacuna monocomponente para la enfermedad del Chagas que comprende al menos un componente seleccionado entre una porción inmunógenica conformada por uno o más polipéptidos recombinantes o sintéticos, o fracciones de ellos y un grupo de polinucleótidos que comprenden a las regiones que codifican a uno o más polipéptidos inmunogénico derivados de los Trypanosoma cruzi ( es decir de un T. Cruzi y/o una región conservada común a varios de ellos), donde la porción inmunógenica o el grupo de polinucleótido estimula una respuesta de anticuerpos, de células T CD4+ sesgadas Th 1 o T CD8+ contra el Tripanosoma cruzi. También se incluyen en la presente invención las composiciones farmacéuticas que contienen dichas vacunas multicomponentes y monocomponentes, procedimientos para la obtención de la porción inmunogena de dichas vacunas y el acido nucleico utilizado en dicho procedimiento.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ARP070104827A AR064593A1 (es) | 2007-10-31 | 2007-10-31 | Una vacuna multicomponente o monocomponente para ser utilizada contra la enfermedad de chagas, composiciones farmaceuticas que las contienen, procedimiento para la obtencion del inmunogeno de dichas vacunas y acido nucleico utilizado en dicho procedimiento. |
Publications (1)
Publication Number | Publication Date |
---|---|
NI201000071A true NI201000071A (es) | 2010-11-10 |
Family
ID=40591558
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NI201000071A NI201000071A (es) | 2007-10-31 | 2010-04-26 | Una vacuna multicomponente o monocompon |
Country Status (18)
Country | Link |
---|---|
US (3) | US8900598B2 (es) |
EP (1) | EP2206513B1 (es) |
AR (1) | AR064593A1 (es) |
BR (1) | BRPI0805753A2 (es) |
CA (1) | CA2702534C (es) |
CO (1) | CO6280407A2 (es) |
CR (1) | CR11334A (es) |
DO (1) | DOP2010000083A (es) |
EC (1) | ECSP10010055A (es) |
ES (1) | ES2569943T3 (es) |
GT (1) | GT201000066A (es) |
HN (1) | HN2010000750A (es) |
MX (1) | MX2010004626A (es) |
NI (1) | NI201000071A (es) |
PA (1) | PA8816401A1 (es) |
PE (2) | PE20091161A1 (es) |
UY (1) | UY31451A1 (es) |
WO (1) | WO2009056965A2 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR064593A1 (es) * | 2007-10-31 | 2009-04-15 | Baeremaecker Barros Carlos De | Una vacuna multicomponente o monocomponente para ser utilizada contra la enfermedad de chagas, composiciones farmaceuticas que las contienen, procedimiento para la obtencion del inmunogeno de dichas vacunas y acido nucleico utilizado en dicho procedimiento. |
WO2011031317A2 (en) | 2009-09-10 | 2011-03-17 | The Board Of Regents Of The University Of Texas System | Vaccine for control of trypanosoma cruzi infection and chagas disease |
CN103890004B (zh) | 2011-07-21 | 2018-02-02 | 西班牙国家研究委员会 | 由具有特定免疫显性表位的婴儿利什曼虫pfr1蛋白片段组成的嵌合分子可用于抗利什曼病的免疫疗法 |
US10279023B2 (en) | 2013-09-24 | 2019-05-07 | Board Of Regents, The University Of Texas System | Mucin-associated surface protein as a vaccine against chagas disease |
US9566320B2 (en) | 2013-09-24 | 2017-02-14 | The Board Of Regents Of The University Of Texas System | Mucin-associated surface protein as vaccine against Chagas disease |
BR112017028052A2 (pt) * | 2015-06-23 | 2018-09-11 | Epivax Inc | peptídeo, método para induzir uma resposta imune em um sujeito e formulação de vacina |
BR102021010469A2 (pt) * | 2021-05-28 | 2022-12-13 | Fundação Oswaldo Cruz | Proteína quimérica recombinante, seu uso, e, composição |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993018787A1 (en) | 1992-03-25 | 1993-09-30 | New York University | Trans-sialidase and methods of use and making thereof |
US6875584B1 (en) * | 1999-03-02 | 2005-04-05 | University Of Georgia Research Foundation, Inc. | Prophylactic and therapeutic immunization against protozoan infection and disease |
US7060676B2 (en) * | 1999-12-20 | 2006-06-13 | Trustees Of Tufts College | T. cruzi-derived neurotrophic agents and methods of use therefor |
US7780969B2 (en) * | 2005-07-15 | 2010-08-24 | University Of Georgia Research Foundation, Inc. | Trypanosoma cruzi proteome compositions and methods |
MX2008011632A (es) * | 2006-03-17 | 2008-10-17 | Vib Vzw | Vacuna novedosa contra infeccion de trypanosoma cruzi. |
AR064593A1 (es) * | 2007-10-31 | 2009-04-15 | Baeremaecker Barros Carlos De | Una vacuna multicomponente o monocomponente para ser utilizada contra la enfermedad de chagas, composiciones farmaceuticas que las contienen, procedimiento para la obtencion del inmunogeno de dichas vacunas y acido nucleico utilizado en dicho procedimiento. |
-
2007
- 2007-10-31 AR ARP070104827A patent/AR064593A1/es unknown
-
2008
- 2008-10-30 PE PE2008001858A patent/PE20091161A1/es not_active Application Discontinuation
- 2008-10-30 EP EP08844056.5A patent/EP2206513B1/en not_active Not-in-force
- 2008-10-30 MX MX2010004626A patent/MX2010004626A/es active IP Right Grant
- 2008-10-30 ES ES08844056.5T patent/ES2569943T3/es active Active
- 2008-10-30 US US12/740,393 patent/US8900598B2/en not_active Expired - Fee Related
- 2008-10-30 PE PE2013002770A patent/PE20140520A1/es active IP Right Grant
- 2008-10-30 WO PCT/IB2008/002923 patent/WO2009056965A2/es active Application Filing
- 2008-10-30 CA CA2702534A patent/CA2702534C/en not_active Expired - Fee Related
- 2008-10-31 UY UY31451A patent/UY31451A1/es not_active Application Discontinuation
- 2008-10-31 BR BRPI0805753-2A patent/BRPI0805753A2/pt not_active Application Discontinuation
-
2009
- 2009-02-19 PA PA20098816401A patent/PA8816401A1/es unknown
-
2010
- 2010-03-15 DO DO2010000083A patent/DOP2010000083A/es unknown
- 2010-03-23 GT GT201000066A patent/GT201000066A/es unknown
- 2010-03-24 CR CR11334A patent/CR11334A/es unknown
- 2010-03-26 EC EC2010010055A patent/ECSP10010055A/es unknown
- 2010-04-21 HN HN2010000750A patent/HN2010000750A/es unknown
- 2010-04-26 NI NI201000071A patent/NI201000071A/es unknown
- 2010-05-18 CO CO10058905A patent/CO6280407A2/es unknown
-
2014
- 2014-10-31 US US14/529,454 patent/US9662378B2/en not_active Expired - Fee Related
-
2017
- 2017-04-20 US US15/492,365 patent/US10213500B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
ES2569943T3 (es) | 2016-05-13 |
US20150056243A1 (en) | 2015-02-26 |
UY31451A1 (es) | 2009-05-29 |
EP2206513B1 (en) | 2016-02-17 |
US10213500B2 (en) | 2019-02-26 |
EP2206513A2 (en) | 2010-07-14 |
PE20140520A1 (es) | 2014-05-05 |
HN2010000750A (es) | 2013-08-19 |
PE20091161A1 (es) | 2009-08-28 |
CO6280407A2 (es) | 2011-05-20 |
US9662378B2 (en) | 2017-05-30 |
MX2010004626A (es) | 2010-10-04 |
DOP2010000083A (es) | 2010-07-15 |
AR064593A1 (es) | 2009-04-15 |
US8900598B2 (en) | 2014-12-02 |
CA2702534C (en) | 2016-10-18 |
GT201000066A (es) | 2012-04-03 |
US20170290896A1 (en) | 2017-10-12 |
CA2702534A1 (en) | 2009-05-07 |
WO2009056965A2 (es) | 2009-05-07 |
PA8816401A1 (es) | 2009-09-17 |
WO2009056965A3 (es) | 2009-07-23 |
CR11334A (es) | 2010-05-26 |
BRPI0805753A2 (pt) | 2012-04-17 |
ECSP10010055A (es) | 2010-06-29 |
US20100297186A1 (en) | 2010-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NI201000071A (es) | Una vacuna multicomponente o monocompon | |
UY39060A (es) | Composiciones y métodos para prevenir y tratar la infección por coronavirus - vacunas sars-cov-2 | |
BR112017017949A2 (pt) | regimes de iniciação-reforço envolvendo administração de pelo menos um constructo de mrna | |
BR112016010383A2 (pt) | compostos de pyy seletivos e usos dos mesmos | |
CR20180589A (es) | Cápsulas variantes de virus adenoasociados y métodos de uso de estas | |
BR112015002131A8 (pt) | Vírus vaccinia ankara modificado (mva) recombinante, composição farmacêutica e uso do referido mva recombinante | |
BR112016015422A2 (pt) | formulações de vacina de frasco único | |
ECSP21023398A (es) | Dosis unitaria de vacuna contra el dengue y administración de esta | |
BR112016004108A2 (pt) | métodos para expressar uma molécula antigênica ou uma parte da mesma e para geração de uma resposta imune, composição farmacêutica, célula ou população de células, usos de uma população de células e de uma molécula antigênica, moléculas antigênica, agentes de fotossensibilização e ligante tlr e agente, produto, e, kit | |
BR112014001409A2 (pt) | métodos e composições para vacinação contra staphylococcus aureus | |
McPherson et al. | Development of a SARS coronavirus vaccine from recombinant spike protein plus delta inulin adjuvant | |
BR112013026661A2 (pt) | método de entrega de vacina | |
DOP2010000188A (es) | Una vacuna de vih que comprende una proteina y un agente estabilizador | |
BR112014017141A2 (pt) | método de tratamento de diabetes usando-se apolipoproteína a-iv não glicosilada | |
SG195115A1 (en) | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of dengue virus infection | |
BR112017022755A2 (pt) | formulações de glucopiranosil lipídeo a e alérgeno a amendoim para administração sublingual | |
UY38707A (es) | Nuevos antagonistas cíclicos del receptor b2 de bradiquinina | |
EA201690115A1 (ru) | Комбинированные иммуногенные композиции | |
BR112017013270A2 (pt) | ?composição de vacina contra vírus da dengue, métodos para induzir uma resposta imune contra dengue, para reduzir a probabilidade de infecção por dengue, ou prevenir ou atenuar os sintomas da mesma, e, uso de uma composição de vacina contra vírus da dengue?. | |
BRPI0512393A (pt) | vacinação de jaritataca e/ou mangusto contra raiva | |
Lane | The current and future landscape of smallpox vaccines | |
BR112018007870A2 (pt) | composição imunogênica, método para a preparação de uma composição imunogênica, composição farmacêutica, vacina, método para estimular uma resposta imune em um paciente | |
CO6280495A2 (es) | Vacuna que contiene un extracto de proteina ribosoma (rpe) y opcionalmente un adyuvante que estimula las th1 | |
Manappallil | Ischemic stroke following Dengue fever: A case report | |
BR112015024882B1 (pt) | Composição, vacina contra carrapatos rhipicephalus, métodos para a preparação de uma composição e de uma vacina contra carrapatos rhipicephalus, proteína bm86 ou homólogo da mesma e uma proteína subolesina ou homólogo da mesma, uso de proteína bm86 ou homólogo da mesma e de uma proteína subolesina ou homólogo da mesma, e, kit de partes |